DOCSLIB.ORG

Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-AROMOLINE 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 4 (+)-CEPHARANTHINE 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 2 (+)-ISOLARICIRESINOL 1 (+)-NORTRACHELOGENIN 1 (+)-PRAERUPTORUM-A 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (+)-TENUIPINE 1 (+)-TETRANDRINE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 1 (-)-APOGLAZIOVINE 2 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANADINE 1 (-)-CURINE 1 Chemical Activity Count (-)-DAURISOLINE 1 (-)-DICENTRINE 1 (-)-EMETINE 1 (-)-EPICATECHIN 3 (-)-EPICATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN 2 (-)-EPIGALLOCATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN-GALLATE 2 (-)-EUDESMIN 1 (-)-HYDROXYJASMONIC-ACID 1 (-)-IBOGAMINE 1 (-)-STEPHOLIDINE 1 (-)-TENUIPINE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 2 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 1-ETHYL-BETA-CARBOLINE 2 1-HYDROXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-METHOXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10,6-HONOKIOL 1 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 2 Chemical Activity Count 10-DEHYDROGINGERDIONE 1 10-GINGERDIONE 1 12-(4'-METHOXYPHENYL)-DAURICINE 1 12-METHOXYDIHYDROCOSTULONIDE 1 13',II8-BIAPIGENIN 1 13-HYDROXYLUPANINE 1 13-OXYINGENOL-ESTER 1 14-ACETOXY-7-BETA-(3'-ETHYL-CROTONOYL-OXY)-NOTONIPETRANONE 1 16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 16-HYDROXYINGENOL-ESTER 1 2'-ANGELOYL-3'-ISOVALERYL-VAGINATE 1 2'-O-GLYCOSYLVITEXIN 1 2,3,7-TRIHYDROXY-5-(3,4-DIHYDROXY-E-STYRYL)-6,7,8,9-TETRAHYDRO-5H- 1 BENZOCYCLOHEPTENE 2,3-DIHYDROXYBENZOIC-ACID 1 2-(3',4-DIPHENYL)-ETHANOL 1 2-BETA,3BETA-27-TRIHYDROXYOLEAN-12-ENE-23,28-DICARBOXYLIC-ACID 1 2-CAFFEOYL-OXY-3-{2-(4-HYDROXYBENZYL)-4,5-DIHYDROXY}PHENYLPROPIONIC-ACID 1 2-METHYLBUT-3-ENE-2-OL 4 2-METHYLCHROMONE 1 20-DEOXYINGENOL-ESTER 1 22BETA-ESCIN 1 24-METHYLENE-CYCLOARTANOL 1 3',4',5,7-TETRAHYDROXYFLAVONE 1 3'-O-METHYL-CATECHIN 1 3,3'-DIMETHYLELLAGIC-ACID 2 3,4,5-TRI-O-CAFFEOYLQUINIC-ACID 1 3,4-DICAFFEOYL-QUINIC-ACID 1 3 Chemical Activity Count 3,4-DIHYDROXYBENZOATE 1 3,4-DIHYDROXYPHENYLETHANOL 1 3,4-DIMETHOXYTOLUENE 1 3,4-HYDROXYCINNAMIC-ACID 1 3,4-METHYLENE-DIOXYCINNAMIC-ACID-BORNYL-ESTER 1 3,4-SECOTRITERPENE-ACID-20-EPI-KOETJAPIC-ACID 1 3,5,8,3',4'-PENTAHYDROXYFLAVONE 1 3,5-DI-O-CAFFEOYLQUINIC-ACID 1 3,5-DICAFFEOYL-QUINIC-ACID 1 3,7,8,2',5'-PENTAHYDROXYFLAVONE 1 3-ACETYLACONITINE 1 3-ALPHA-DIHYDROCADAMBINE 1 3-BETA-23,28-TRIHYDROXY-12-OLEANENE-23-CAFFEATE 1 3-BETA-23,28-TRIHYDROXY-12-OLEANENE-3-BETA-CAFFEATE 1 3-BETA-HYDROXY-2,3-DIHYDROWITHANOLIDE-F 2 3-BETA-TRANS-(3,4-DIHYDROXYCINNAMOYLOXY)-20(29)-LUPEN-28-OIC-ACID 1 3-BETA-TRANS-(3,4-DIHYDROXYCINNAMOYLOXY)-OLEAN-12-EN-28-OIC-ACID 1 3-BETA-TRANS-(3,4-DIHYDROXYCINNAMOYLOXY)-OLEAN-18-EN-28-OIC-ACID 1 3-HYDROXY-FLAVONE 1 3-N-BUTYL-PHTHALIDE 3 3-O-ACETYLOLEANOLIC-ACID 1 3-O-CAFFEOYLQUINIC-ACID 1 3-OXO-11-ALPHA-HYDROXYOLEAN-12-ENE-30-OIC-ACID 1 3-OXO-11-ALPHA-METHOXYOLEAN-12-ENE-30-OIC-ACID 1 3-OXO-OLEAN-9(11),12-DIENE-30-OIC-ACID 1 4,5-DI-O-CAFFEOYLQUINIC-ACID 1 4,5-EPOXYOVATODIOLIDE 1 4 Chemical Activity Count 4-ACETYLARABINOSYL-ELLAGIC-ACID 1 4-ACETYLXYLOSYL-ELLAGIC-ACID 1 4-ALLYL-PYROCATECHOL 1 4-AMINO-4-CARBOXYCHROMAN-2-ONE 2 4-ARABINOSYL-ELLAGIC-ACID 1 4-HYDROXY-TRITRIACONTANE-16,18-DIONE 1 4-KETOPINORESINOL 1 4-METHYLENE-MILTIRONE 1 4-O-CAFFEOYLQUINIC-ACID 1 4-O-METHYL-GLUCURONOXYLAN 1 4-TERPINEOL 1 4-VINYL-GUAIACOL 1 5,6-DI-C-GLUCOSYLAPIGENIN 1 5,7-DIHYDROXYCOUMARIN-7-METHYL-ETHER 1 5,7-DIMETHOXYFLAVONE 1 5,8-DIHYDROXYBENZOPYRANONE 1 5-DEOXYINGENOL-ESTER 1 5-HYDROXY-8-O-BETA-D-GLUCOPYRANOSYL-BENZOPYRANONE 1 5-HYDROXYTRYPTAMINE 1 5-HYDROXYTRYPTOPHAN 1 5-METHOXY-N,N-DIMETHYLTRYPTAMINE 1 5-METHOXY-PSORALEN 1 5-O-BETA-D-GLUCOPYRANOSYL-3-1-(4-PHENYL)-DECANE 1 5-O-CAFFEOYLQUINIC-ACID 1 5-[2-(ACETOXY)-3-HYDROXY-3-METHYLBUTOXY]-PSORALEN 1 6'-O-ACETYL-DAIDZIN 1 6'-O-ACETYL-GENISTIN 1 5 Chemical Activity Count 6,7,4'-TRIHYDROXYISOFLAVAN 1 6,7,4'-TRIHYDROXYISOFLAVANONE 1 6,7,4'-TRIHYDROXYISOFLAVONE 1 6,7-DI-4'-METHOXYISOFLAVAN 1 6,7-DI-4'-METHOXYISOFLAVANONE 1 6,7-DI-4'-METHOXYISOFLAVONE 1 6,7-DIHYDROXY-4'-METHOXYISOFLAVAN 1 6,7-DIHYDROXY-4'-METHOXYISOFLAVANONE 1 6,7-DIHYDROXY-4'-METHOXYISOFLAVONE 1 6,7-DIHYDROXYCOUMARIN 1 6,7-DIMETHYLAESCULETIN 1 6,7-DIMETHYLESCULETIN 1 6-DEHYDROGINGERDIONE 1 6-DEOXYJACAREUBIN 1 6-GINGERDIOL 1 6-GINGERDIONE 1 6-GINGEROL 3 6-METHOXY-BENZOLINONE 1 6-METHOXYBENZOXAZOLINONE 1 6-O-(2''-ACETYL-3'',4''-O-DI-P-METHOXYCINNAMOYL-ALPHA-L-RHAMNOPYRANOSYL)-CATALPOL 1 6-O-(4''-ACETYL-2'',3''-O-DI-P-METHOXYCINNAMOYL-ALPHA-L-RHAMNOPYRANOSYL)-CATALPOL 1 6-SHOGAOL 4 7,8-DIHYDROXYFLAVONE 1 7-METHOXYCOUMARIN 1 7-METHYLJUGLONE 1 7-N-BUTOXY-3,2',5'-TRIHYDROXYFLAVONE 1 7-[3-(3,4-DIHYDROXY-4-HYDROXYMETHYL-TETRAHYDRO-FURAN-2-YLOXY)-4,5-DIHYDROXY-6- 1 HYDROXYMETHYL-TETRAHYDRO-PYRAN-2-YLOXY]...
Load more

Recommended publications
  • Régulation De L'inflammation Par Les Lipides Bioactifs : Interactions Biosynthétiques Et Fonctionnelles Entre Les Endocannabinoïdes Et Les Éicosanoïdes
    Régulation de l'inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Doctorat en microbiologie-immunologie Philosophiæ doctor (Ph. D.) Québec, Canada © Caroline Turcotte, 2019 Régulation de l’inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Sous la direction de : Nicolas Flamand, directeur de recherche Marie-Renée Blanchet, codirectrice de recherche Résumé Les maladies inflammatoires chroniques sont un fardeau de santé important à travers le monde. Les traitements actuellement disponibles soulagent la douleur et l’inflammation, mais leurs effets secondaires rendent leur utilisation à long terme risquée. À la lumière de cette problématique, la communauté scientifique s’intéresse au potentiel d’anti-inflammatoires naturels comme les endocannabinoïdes. Les endocannabinoïdes sont des lipides endogènes qui activent les récepteurs cannabinoïdes (CB1 et CB2). Ils régulent ainsi divers processus physiologiques tels l’appétit, l’adipogénèse et la nociception. Les deux endocannabinoïdes les mieux caractérisés, le 2-AG et l’AEA, peuvent également moduler l’inflammation en activant le récepteur CB2 à la surface des cellules immunitaires. Les souris déficientes pour le récepteur CB2 présentent un phénotype inflammatoire exacerbé, suggérant que ce récepteur est anti-inflammatoire. Cependant, le rôle des endocannabinoïdes dans l’inflammation est beaucoup plus complexe puisqu’ils peuvent être métabolisés en une grande variété de médiateurs lipidiques de l’inflammation. Leur voie de dégradation principale est leur hydrolyse en acide arachidonique (AA), qui sert de précurseur à la biosynthèse d’éicosanoïdes pro-inflammatoires comme le leucotriène B4 et la prostaglandine E2. Ils peuvent également être métabolisés directement par certaines enzymes impliquées dans la synthèse d’éicosanoïdes, pour générer des médiateurs comme les prostaglandines-glycérol (PG-G).
    [Show full text]
  • An in Vivo Examination of the Differences Between Rapid
    www.nature.com/scientificreports OPEN An in vivo examination of the diferences between rapid cardiovascular collapse and prolonged hypotension induced by snake venom Rahini Kakumanu1, Barbara K. Kemp-Harper1, Anjana Silva 1,2, Sanjaya Kuruppu3, Geofrey K. Isbister 1,4 & Wayne C. Hodgson1* We investigated the cardiovascular efects of venoms from seven medically important species of snakes: Australian Eastern Brown snake (Pseudonaja textilis), Sri Lankan Russell’s viper (Daboia russelii), Javanese Russell’s viper (D. siamensis), Gaboon viper (Bitis gabonica), Uracoan rattlesnake (Crotalus vegrandis), Carpet viper (Echis ocellatus) and Puf adder (Bitis arietans), and identifed two distinct patterns of efects: i.e. rapid cardiovascular collapse and prolonged hypotension. P. textilis (5 µg/kg, i.v.) and E. ocellatus (50 µg/kg, i.v.) venoms induced rapid (i.e. within 2 min) cardiovascular collapse in anaesthetised rats. P. textilis (20 mg/kg, i.m.) caused collapse within 10 min. D. russelii (100 µg/kg, i.v.) and D. siamensis (100 µg/kg, i.v.) venoms caused ‘prolonged hypotension’, characterised by a persistent decrease in blood pressure with recovery. D. russelii venom (50 mg/kg and 100 mg/kg, i.m.) also caused prolonged hypotension. A priming dose of P. textilis venom (2 µg/kg, i.v.) prevented collapse by E. ocellatus venom (50 µg/kg, i.v.), but had no signifcant efect on subsequent addition of D. russelii venom (1 mg/kg, i.v). Two priming doses (1 µg/kg, i.v.) of E. ocellatus venom prevented collapse by E. ocellatus venom (50 µg/kg, i.v.). B. gabonica, C. vegrandis and B.
    [Show full text]
  • Toxicology in Antiquity
    TOXICOLOGY IN ANTIQUITY Other published books in the History of Toxicology and Environmental Health series Wexler, History of Toxicology and Environmental Health: Toxicology in Antiquity, Volume I, May 2014, 978-0-12-800045-8 Wexler, History of Toxicology and Environmental Health: Toxicology in Antiquity, Volume II, September 2014, 978-0-12-801506-3 Wexler, Toxicology in the Middle Ages and Renaissance, March 2017, 978-0-12-809554-6 Bobst, History of Risk Assessment in Toxicology, October 2017, 978-0-12-809532-4 Balls, et al., The History of Alternative Test Methods in Toxicology, October 2018, 978-0-12-813697-3 TOXICOLOGY IN ANTIQUITY SECOND EDITION Edited by PHILIP WEXLER Retired, National Library of Medicine’s (NLM) Toxicology and Environmental Health Information Program, Bethesda, MD, USA Academic Press is an imprint of Elsevier 125 London Wall, London EC2Y 5AS, United Kingdom 525 B Street, Suite 1650, San Diego, CA 92101, United States 50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom Copyright r 2019 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions. This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).
    [Show full text]
  • Regulation of Brain Reward by the Endocannabinoid System: a Critical Review of Behavioral Studies in Animals
    Send Orders for Reprints to [email protected] Current Pharmaceutical Design, 2014, 20, 000-000 1 Regulation of Brain Reward by the Endocannabinoid System: A Critical Review of Behavioral Studies in Animals S. Vlachou2 and G. Panagis1,* 1Laboratory of Behavioral Neuroscience, Department of Psychology, School of Social Sciences, University of Crete, 74100 Rethym- non, Crete, Greece; 2School of Nursing and Human Sciences, Faculty of Science and Health, Dublin City University, Glasnevin, Dub- lin 9, Ireland Abstract: The endocannabinoid system has been implicated in the regulation of a variety of physiological processes, including a crucial involvement in brain reward systems and the regulation of motivational processes. Behavioral studies have shown that cannabinoid re- ward may involve the same brain circuits and similar brain mechanisms with other drugs of abuse, such as nicotine, cocaine, alcohol and heroin, as well as natural rewards, such as food, water and sucrose, although the conditions under which cannabinoids exert their reward- ing effects may be more limited. The purpose of the present review is to briefly describe and evaluate the behavioral and pharmacological research concerning the major components of the endocannabinoid system and reward processes. Special emphasis is placed on data re- ceived from four procedures used to test the effects of the endocannabinoid system on brain reward in animals; namely, the intracranial self-stimulation paradigm, the self-administration procedure, the conditioned place preference procedure and the drug-discrimination pro- cedure. The effects of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor agonists, antagonists and endocannabinoid modulators in these procedures are examined. Further, the involvement of CB1 and CB2 receptors, as well the fatty acid amid hydrolase (FAAH) en- zyme in reward processes is investigated through presentation of respective genetic ablation studies in mice.
    [Show full text]
  • Neurotoxicity in Snakebite—The Limits of Our Knowledge
    Review Neurotoxicity in Snakebite—The Limits of Our Knowledge Udaya K. Ranawaka1*, David G. Lalloo2, H. Janaka de Silva1 1 Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka, 2 Liverpool School of Tropical Medicine, Liverpool, United Kingdom been well described with pit vipers (family Viperidae, subfamily Abstract: Snakebite is classified by the WHO as a Crotalinae) such as rattlesnakes (Crotalus spp.) [58–67]. Although neglected tropical disease. Envenoming is a significant considered relatively less common with true vipers (family public health problem in tropical and subtropical regions. Viperidae, subfamily Viperinae), neurotoxicity is well recognized Neurotoxicity is a key feature of some envenomings, and in envenoming with Russell’s viper (Daboia russelii) in Sri Lanka and there are many unanswered questions regarding this South India [9,68–75], the asp viper (Vipera aspis) [76–82], the manifestation. Acute neuromuscular weakness with respi- adder (Vipera berus) [83–85], and the nose-horned viper (Vipera ratory involvement is the most clinically important ammodytes) [86,87]. neurotoxic effect. Data is limited on the many other acute neurotoxic manifestations, and especially delayed Acute neuromuscular paralysis is the main type of neurotoxicity neurotoxicity. Symptom evolution and recovery, patterns and is an important cause of morbidity and mortality related to of weakness, respiratory involvement, and response to snakebite. Mechanical ventilation, intensive care, antivenom antivenom and acetyl cholinesterase inhibitors are vari- treatment, other ancillary care, and prolonged hospital stays all able, and seem to depend on the snake species, type of contribute to a significant cost of provision of care. And ironically, neurotoxicity, and geographical variations. Recent data snakebite is common in resource-poor countries that can ill afford have challenged the traditional concepts of neurotoxicity such treatment costs.
    [Show full text]
  • United States Patent [191 [11] Patent Number: 4,758,639 Koyanagi Et Al
    United States Patent [191 [11] Patent Number: 4,758,639 Koyanagi et al. [45] Date of Patent: Jul. 19, 1988 [54] PROCESS FOR PRODUCTION OF VINYL [56] References Cited POLYMER . U.S. PATENT DOCUMENTS [75] Inventors: Shunichi Koyanagi, Yokohama; 3,923,765 12/1975 Goetze et al. ....................... .. 526/62 Hajime Kutamura, Ichihara; 4,049,895 9/1977 McOnie et al. ..... .. 526/62 Toshihide Shimizu; Ichiro Kaneko, 4,539,230 9/ 1985 Shimizu et al. ................. .. 526/62 X both of Ibaraki, all of Japan Primary Examiner-Joseph L. Schofer Assistant Examiner-F. M. Teskin [73] Assignee: Shin-Etsu Chemical Co., Ltd., Tokyo, Attorney, Agent, or Firm—0blon, Fisher, Spivak, Japan McClelland & Maier [21] Appl. No.: 94,020 [57] ABSTRACT [22] Filed: Sep. 3, 1987 A process for production of a vinyl polymer by suspen sion polymerization or emulsion polymerization of at Related US. Application Data least one kind of vinyl monomer in an aqueous medium is disclosed. [63] Continuation of Ser. No. 765,803, Aug. 15, 1985, aban In this process, the polymerization is carried out in a cloned. polymerizer, the inner wall surface and portions of the [30] Foreign Application Priority Data auxiliary equipment thereof which may come into contact with the monomer during polymerization hav Aug. 17, 1984 [JP] Japan ........ .. .. 59471045 ing a surface roughness of not greater than 5 pm and Aug. 17, 1984 [JP] Japan .............................. .. 59-171046 being previously coated with a scaling preventive com [51] Int. Cl.‘ ......................... .. C08F 2/18; C08F 2/22; prising at least one selected from dyes, pigments and CO8F 2/44 aromatic or heterocyclic compounds having at least 5 [52] US.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • In the Molecular Evolution of Snake Venom Proteins Robin Doley National University of Singapore
    University of Northern Colorado Scholarship & Creative Works @ Digital UNC School of Biological Sciences Faculty Publications School of Biological Sciences 2009 Role of Accelerated Segment Switch in Exons to Alter Targeting (Asset) in the Molecular Evolution of Snake Venom Proteins Robin Doley National University of Singapore Stephen P. Mackessy University of Northern Colorado R. Manjunatha Kini National University of Singapore Follow this and additional works at: http://digscholarship.unco.edu/biofacpub Part of the Biology Commons Recommended Citation Doley, Robin; Mackessy, Stephen P.; and Kini, R. Manjunatha, "Role of Accelerated Segment Switch in Exons to Alter Targeting (Asset) in the Molecular Evolution of Snake Venom Proteins" (2009). School of Biological Sciences Faculty Publications. 7. http://digscholarship.unco.edu/biofacpub/7 This Article is brought to you for free and open access by the School of Biological Sciences at Scholarship & Creative Works @ Digital UNC. It has been accepted for inclusion in School of Biological Sciences Faculty Publications by an authorized administrator of Scholarship & Creative Works @ Digital UNC. For more information, please contact [email protected]. BMC Evolutionary Biology BioMed Central Research article Open Access Role of accelerated segment switch in exons to alter targeting (ASSET) in the molecular evolution of snake venom proteins Robin Doley1, Stephen P Mackessy2 and R Manjunatha Kini*1 Address: 1Protein Science Laboratory, Department of Biological Sciences, National University of
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Composition Modulating Botulinum Neurotoxin Effect
    (19) *EP003753568A1* (11) EP 3 753 568 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.12.2020 Bulletin 2020/52 A61K 38/17 (2006.01) A61K 31/205 (2006.01) A61K 31/4178 (2006.01) A61K 38/48 (2006.01) (2006.01) (2006.01) (21) Application number: 19181635.4 A61P 9/00 A61P 21/00 A61P 29/00 (2006.01) (22) Date of filing: 21.06.2019 (84) Designated Contracting States: •Cros, Cécile AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 74580 Viry (FR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Hulo, Nicolas PL PT RO RS SE SI SK SM TR 1252 Meinier (CH) Designated Extension States: • Machicoane, Mickaël BA ME 1290 Versoix (CH) Designated Validation States: KH MA MD TN (74) Representative: Barbot, Willy Simodoro-ip (71) Applicant: Fastox Pharma SA 82, rue Sylvabelle 1003 Lausanne (CH) 13006 Marseille (FR) (72) Inventors: • Le Doussal, Jean-Marc 1007 Lausanne (CH) (54) COMPOSITION MODULATING BOTULINUM NEUROTOXIN EFFECT (57) The present invention relates to a method for cholinergic neuronal transmission to the botulinum neu- modulating the effect of a botulinum neurotoxin compo- rotoxin composition. The invention also relates to com- sition, that is accelerating the onset of action and /or ex- positions comprising at least one postsynaptic inhibitor tending the duration of action and/or enhancing the in- of cholinergic neuronal transmission and a botulinum tensity of action of a botulinum neurotoxin composition, neurotoxin, and their uses for treating aesthetic or ther- comprising adding at least one postsynaptic inhibitor of apeutic conditions.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,123,943 Baba Et Al
    USOO61239.43A United States Patent (19) 11 Patent Number: 6,123,943 Baba et al. (45) Date of Patent: Sep. 26, 2000 54 NF-KBACTIVITY INHIBITOR 8-301761 11/1996 Japan ............................. A61K 31/47 75 Inventors: Masanori Baba, Kagoshima; Minoru OTHER PUBLICATIONS Ono, Tokyo, both of Japan Sato et al. Eur. J. Pharmacol. (1982) 83: 91-95. 73 Assignee: Kaken Shoyaku Co., Ltd., Tokyo, Japan Primary Examiner Jean C. Witz Attorney, Agent, or Firm Sughrue, Mion, Zinn, Macpeak 21 Appl. No.: 09/037,712 & Seas, PLLC 22 Filed: Mar 10, 1998 57 ABSTRACT 30 Foreign Application Priority Data This invention relates to an NF-kB activity inhibitor which contains alkaloids originated from a plant belonging to the Dec. 22, 1997 JP Japan .................................... 9-353879 genus Stephania of the family Menspermaceae, derivatives thereof and Salts thereof, as the active components, to an (51) Int. Cl." ..................................................... A61K 35/78 agent for use in the treatment and prevention of diseases 52 U.S. Cl. ....................... 424/195.1; 514/308; 514/387; upon which the NF-kB activity inhibiting action is effective 514/415 and to an inhibitor of the expression of related genes. Since 58 Field of Search ......................... 424/195.1; 514/387, Said active components exert an action to inhibit transcrip 514/308, 415; 546/140,139; 534/790 tion of DNA having an NF-kB recognition sequence by inhibiting the activity of NF-kB, the drug of the present 56) References Cited invention can inhibit expression of genes of certain Sub U.S. PATENT DOCUMENTS stances Such as cytokines, inflammatory cytokine receptor antagonists, MHC class I, MHC class II, B2 microglobulin, 5,025,020 6/1991 Van Dyke ..............................
    [Show full text]
  • Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57bl/6J Mice
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2013 Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57Bl/6J Mice Jason Wiebelhaus Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Psychology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/555 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Jason Michael Wiebelhaus, 2013 All Rights Reserved Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57Bl/6J Mice Dissertation to be submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University By: Jason M. Wiebelhaus Master of Science, Virginia Commonwealth University, 2009 Bachelor of Science, University of WI-Eau Claire, 2006 Co-Directors: Aron H. Lichtman1, Ph.D. and Joseph H. Porter2, Ph.D. 1, 2Professors 1Department of Pharmacology and Toxicology, 2Department of Psychology Virginia Commonwealth University Richmond, VA September, 2013 ii Acknowledgement I owe my thanks to many people who helped me throughout the process of conducting these experiments and writing my dissertation. First and foremost I would like to thank my mentor and dissertation co-director director Aron H. Lichtman for his guidance and patience throughout my years of graduate school at Virginia Commonwealth University. I would also like to thank my committee members Joseph H.
    [Show full text]